{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:10Z","timestamp":1792670830482,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oral vitamin K antagonists (VKAs), warfarin, have been in routine clinical use for almost 70\u00a0years for various cardiovascular conditions. Direct-Acting Oral Anticoagulants (DOACs) have emerged as competitive alternatives for VKAs to prevent stroke in patients with non-valvular atrial fibrillation (AF) and have become the preferred choice in several clinical indications for anticoagulation. Recent guidelines have limited the use of DOACs to patients with non-valvular AF to reduce the risk of cardioembolic complications and to treat venous thromboembolism (VTE). Although emerging evidence is suggestive of its high efficacy, there was a lack of data to support DOACs safety profile in patients with mechanical valve prosthesis, intracardiac thrombi, or other conditions such as cardiac device implantation or catheter ablation. Therefore, several clinical trials have been conducted to assess the beneficial effects of using DOACs, instead of VKAs, for various non-guideline-approved indications. This review aimed to discuss the current guideline-approved indications for DOACs, advantages, and limitations of DOACs use in various clinical indications highlighting the potential emerging indications and remaining challenges for DOACs use. Several considerations are in favour of switching from warfarin to DOACs including superior efficacy, better adverse effect profile, fewer drug-drug interactions, and they do not require frequent international normalized ratio (INR) monitoring. Large randomized controlled trials are required to determine the safety and efficacy of their use in various clinical indications.<\/jats:p>","DOI":"10.1186\/s43044-022-00259-9","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:03:18Z","timestamp":1648512198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!"],"prefix":"10.1186","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-9049","authenticated-orcid":false,"given":"Mahmoud","family":"Abdelnabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthipong","family":"Benjanuwattra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Okasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Almaghraby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehia","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Gerges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"259_CR1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","volume":"62","author":"M Pirmohamed","year":"2006","unstructured":"Pirmohamed M (2006) Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 62:509\u2013511","journal-title":"Br J Clin Pharmacol"},{"key":"259_CR2","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Mu\u00f1oz D, Rosenhek R, Sj\u00f6gren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL (2017) 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38:2739\u20132791","journal-title":"Eur Heart J"},{"key":"259_CR3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","volume":"50","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 50:e1\u2013e88","journal-title":"Eur J Cardiothorac Surg"},{"key":"259_CR4","first-page":"295","volume":"95","author":"J Wilbur","year":"2017","unstructured":"Wilbur J, Shian B (2017) Deep venous thrombosis and pulmonary embolism: current therapy. Am Fam Phys 95:295\u2013302","journal-title":"Am Fam Phys"},{"key":"259_CR5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/10245330500276451","volume":"10","author":"F Newall","year":"2005","unstructured":"Newall F, Monagle P, Johnston L (2005) Patient understanding of warfarin therapy: a review of education strategies. Hematology 10:437\u2013442","journal-title":"Hematology"},{"key":"259_CR6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1368-5031.2006.00790.x","volume":"60","author":"L Boulanger","year":"2006","unstructured":"Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J (2006) Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 60:258\u2013264","journal-title":"Int J Clin Pract"},{"key":"259_CR7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/hrt.2004.042465","volume":"91","author":"M Jones","year":"2005","unstructured":"Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ (2005) Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 91:472\u2013477","journal-title":"Heart"},{"key":"259_CR8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","volume":"139","author":"LA Linkins","year":"2003","unstructured":"Linkins LA, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139:893\u2013900","journal-title":"Ann Intern Med"},{"key":"259_CR9","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","volume":"35","author":"CH Yeh","year":"2015","unstructured":"Yeh CH, Hogg K, Weitz JI (2015) Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol 35:1056\u20131065","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"259_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/VHRM.S79065","volume":"11","author":"J Ment","year":"2015","unstructured":"Ment J (2015) Direct oral anticoagulants: key considerations for use to prevent stroke in patients with non-valvular atrial fibrillation. Vasc Health Risk Manag 11:317\u2013332","journal-title":"Vasc Health Risk Manag"},{"key":"259_CR11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"259_CR12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"259_CR13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"259_CR14","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, \u0160pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104","journal-title":"N Engl J Med"},{"key":"259_CR15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/03007995.2017.1411793","volume":"34","author":"S Deitelzweig","year":"2018","unstructured":"Deitelzweig S, Farmer C, Luo X, Li X, Vo L, Mardekian J, Fahrbach K, Ashaye A (2018) Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Curr Med Res Opin 34:487\u2013498","journal-title":"Curr Med Res Opin"},{"key":"259_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43044-021-00194-1","volume":"73","author":"Y Waranugraha","year":"2021","unstructured":"Waranugraha Y, Rizal A, Syaban MFR, Faratisha IFD, Erwan NE, Yunita KC (2021) Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences. Egypt Heart J 73:1\u201317","journal-title":"Egypt Heart J"},{"key":"259_CR17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, Boriani G, Castella M, Dan G-A, Dilaveris PE (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373\u2013498","journal-title":"Eur Heart J"},{"key":"259_CR18","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidb\u00fcchel H (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330\u20131393","journal-title":"Eur Heart J"},{"key":"259_CR19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","volume":"17","author":"H Heidbuchel","year":"2015","unstructured":"Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467\u20131507","journal-title":"Europace"},{"key":"259_CR20","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/europace\/eux240","volume":"19","author":"GY Lip","year":"2017","unstructured":"Lip GY, Collet JP, Caterina RD, Fauchier L, Lane DA, Larsen TB, Marin F, Morais J, Narasimhan C, Olshansky B (2017) Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Ep Europace 19:1757\u20131758","journal-title":"Ep Europace"},{"key":"259_CR21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R (2022) 2021 ESC\/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 43:561\u2013632","journal-title":"Eur Heart J"},{"key":"259_CR22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, J\u00fcni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42:1289\u20131367","journal-title":"Eur Heart J"},{"key":"259_CR23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509\u20131524","journal-title":"N Engl J Med"},{"key":"259_CR24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 394:1335\u20131343","journal-title":"Lancet"},{"key":"259_CR25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513\u20131524","journal-title":"N Engl J Med"},{"key":"259_CR26","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423\u20132434","journal-title":"N Engl J Med"},{"key":"259_CR27","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW (2019) 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the society of thoracic surgeons. Circulation 140:e125\u2013e151","journal-title":"Circulation"},{"key":"259_CR28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315\u2013352","journal-title":"Chest"},{"key":"259_CR29","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 141:e419S-e496S","journal-title":"Chest"},{"issue":"41","key":"259_CR30","first-page":"543","volume":"2020","author":"SV Konstantinides","year":"2019","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jim\u00e9nez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, F N\u00c1, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E and Zamorano JL. (2019) ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020(41):543\u2013603","journal-title":"Eur Heart J"},{"key":"259_CR31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799\u2013808","journal-title":"N Engl J Med"},{"key":"259_CR32","doi-asserted-by":"crossref","unstructured":"(2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287\u20131297","DOI":"10.1056\/NEJMoa1113572"},{"key":"259_CR33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764\u2013772","journal-title":"Circulation"},{"key":"259_CR34","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342\u20132352","journal-title":"N Engl J Med"},{"key":"259_CR35","doi-asserted-by":"crossref","unstructured":"(2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499\u20132510","DOI":"10.1056\/NEJMoa1007903"},{"key":"259_CR36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, B\u00fcller HR (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615\u2013624","journal-title":"N Engl J Med"},{"key":"259_CR37","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36:2017\u20132023","journal-title":"J Clin Oncol"},{"key":"259_CR38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1160\/TH16-08-0602","volume":"116","author":"JS Ginsberg","year":"2016","unstructured":"Ginsberg JS, Crowther MA (2016) Direct oral anticoagulants (DOACs) and pregnancy: a plea for better information. Thromb Haemost 116:590\u2013591","journal-title":"Thromb Haemost"},{"key":"259_CR39","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/jth.13366","volume":"14","author":"H Cohen","year":"2016","unstructured":"Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R (2016) Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 14:1673\u20131676","journal-title":"J Thromb Haemost"},{"key":"259_CR40","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","volume":"19","author":"P Zhang","year":"2009","unstructured":"Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY (2009) Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett 19:2179\u20132185","journal-title":"Bioorg Med Chem Lett"},{"key":"259_CR41","first-page":"343","volume":"11","author":"NC Chan","year":"2015","unstructured":"Chan NC, Bhagirath V, Eikelboom JW (2015) Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag 11:343\u2013351","journal-title":"Vasc Health Risk Manag"},{"key":"259_CR42","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1517\/13543784.2013.825605","volume":"22","author":"M Palladino","year":"2013","unstructured":"Palladino M, Merli G, Thomson L (2013) Evaluation of the oral direct factor Xa inhibitor\u2014 betrixaban. Expert Opin Investig Drugs 22:1465\u20131472","journal-title":"Expert Opin Investig Drugs"},{"key":"259_CR43","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.V120.21.2266.2266","volume":"120","author":"A Hutchaleelaha","year":"2012","unstructured":"Hutchaleelaha A, Ye C, Song Y, Lorenz T, Gretler D, Lambing J (2012) Metabolism and disposition of betrixaban and its lack of interaction with major CYP enzymes. Blood 120:2266\u20132266","journal-title":"Blood"},{"key":"259_CR44","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-016-0623-7","volume":"18","author":"V Dufrost","year":"2016","unstructured":"Dufrost V, Risse J, Zuily S, Wahl D (2016) Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep 18:74","journal-title":"Curr Rheumatol Rep"},{"key":"259_CR45","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.17219\/acem\/65853","volume":"25","author":"A Undas","year":"2016","unstructured":"Undas A, G\u00f3ralczyk T (2016) Direct oral anticoagulants in patients with thrombophilia: challenges in diagnostic evaluation and treatment. Adv Clin Exp Med 25:1321\u20131330","journal-title":"Adv Clin Exp Med"},{"key":"259_CR46","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132:1365\u20131371","journal-title":"Blood"},{"key":"259_CR47","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"259_CR48","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/europace\/eux240","volume":"19","author":"GYH Lip","year":"2017","unstructured":"Lip GYH, Collet JP, Caterina R, Fauchier L, Lane DA, Larsen TB, Marin F, Morais J, Narasimhan C, Olshansky B, Pierard L, Potpara T, Sarrafzadegan N, Sliwa K, Varela G, Vilahur G, Weiss T, Boriani G, Rocca B (2017) Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE). Europace 19:1757\u20131758","journal-title":"Europace"},{"key":"259_CR49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.5152\/AnatolJCardiol.2015.6285","volume":"15","author":"A Yan\u0131ko\u011flu","year":"2015","unstructured":"Yan\u0131ko\u011flu A, Alt\u0131nta\u015f MS, Ekin\u00f6z\u00fc \u0130 (2015) Dissolution of an apical thrombus by apixaban in a patient with old anteroseptal myocardial infarction. Anatol J Cardiol 15:671\u2013672","journal-title":"Anatol J Cardiol"},{"key":"259_CR50","first-page":"335","volume":"44","author":"A Kaya","year":"2016","unstructured":"Kaya A, Hay\u0131ro\u011flu M, Keskin M, Tekke\u015fin A, Alper AT (2016) Resolution of left ventricular thrombus with apixaban in a patient with hypertrophic cardiomyopathy. Turk Kardiyol Dern Ars 44:335\u2013337","journal-title":"Turk Kardiyol Dern Ars"},{"key":"259_CR51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ihj.2015.06.010","volume":"67","author":"S Kolekar","year":"2015","unstructured":"Kolekar S, Munjewar C, Sharma S (2015) Dabigatran for left ventricular thrombus. Indian Heart J 67:495\u2013496","journal-title":"Indian Heart J"},{"key":"259_CR52","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5853\/jos.2015.17.3.366","volume":"17","author":"K Chung","year":"2015","unstructured":"Chung K, Paek YM, Lee HJ, Hong K-S (2015) Dabigatran effect on left ventricular thrombus in a patient with acute ischemic stroke. J Stroke 17:366\u2013368","journal-title":"J Stroke"},{"key":"259_CR53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2217\/fca.14.12","volume":"10","author":"M Padilla P\u00e9rez","year":"2014","unstructured":"Padilla P\u00e9rez M, Salas Bravo D, Garcel\u00e1n Trigo JA, Vazquez Ruiz de Castroviejo E, Torres Llergo J, Lozano Cabezas C, Fern\u00e1ndez Guerrero JC (2014) Resolution of left ventricular thrombus by rivaroxaban. Future Cardiol 10:333\u2013336","journal-title":"Future Cardiol"},{"key":"259_CR54","doi-asserted-by":"crossref","first-page":"232470961769799","DOI":"10.1177\/2324709617697991","volume":"5","author":"R Seecheran","year":"2017","unstructured":"Seecheran R, Seecheran V, Persad S, Seecheran NA (2017) Rivaroxaban as an antithrombotic agent in a patient with ST-segment elevation myocardial infarction and left ventricular thrombus: a case report. J Investig Med High Impact Case Rep 5:2324709617697991","journal-title":"J Investig Med High Impact Case Rep"},{"key":"259_CR55","first-page":"47","volume":"21","author":"M Abdelnaby","year":"2019","unstructured":"Abdelnaby M, Almaghraby A, Abdelkarim O, Saleh Y, Hammad B, Badran H (2019) The role of rivaroxaban in left ventricular thrombi. Anatol J Cardiol 21:47\u201350","journal-title":"Anatol J Cardiol"},{"key":"259_CR56","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2021.01.049","volume":"77","author":"M Abdelnabi","year":"2021","unstructured":"Abdelnabi M, Saleh Y, Fareed A, Nossikof A, Wang L, Morsi M, Eshak N, Abdelkarim O, Badran H, Almaghraby A (2021) Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial). J Am Coll Cardiol 77:1590\u20131592","journal-title":"J Am Coll Cardiol"},{"key":"259_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvab057","author":"R Alcalai","year":"2021","unstructured":"Alcalai R, Butnaru A, Moravsky G, Yagel O, Rashad R, Ibrahimli M, Planer D, Amir O, Elbaz-Greener G, Leibowitz D (2021) Apixaban vs warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial. Eur Heart J Cardiovasc Pharmacother. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab057","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"259_CR58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.amjcard.2021.09.009","volume":"161","author":"Y Saleh","year":"2021","unstructured":"Saleh Y, Al-Abcha A, Abdelkarim O, Elwany M, Abdelfattah OM, Abdelnabi M, Almaghraby A (2021) Meta-analysis comparing the effect of rivaroxaban versus vitamin K antagonists for treatment of left ventricular thrombi. Am J Cardiol 161:123\u2013125","journal-title":"Am J Cardiol"},{"key":"259_CR59","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1161\/STROKEAHA.115.011273","volume":"46","author":"S Yaghi","year":"2015","unstructured":"Yaghi S, Song C, Gray WA, Furie KL, Elkind MSV, Kamel H (2015) Left atrial appendage function and stroke risk. Stroke 46:3554\u20133559","journal-title":"Stroke"},{"key":"259_CR60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11239-012-0747-1","volume":"34","author":"A Vidal","year":"2012","unstructured":"Vidal A, Vanerio G (2012) Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis 34:545\u2013547","journal-title":"J Thromb Thrombolysis"},{"key":"259_CR61","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ccr3.933","volume":"5","author":"T Koyama","year":"2017","unstructured":"Koyama T, Otsuka Y, Kawahara M, Imoto Y, Nakamura K, Kodama S, Noguchi H (2017) A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban. Clin Case Rep 5:711\u2013713","journal-title":"Clin Case Rep"},{"key":"259_CR62","doi-asserted-by":"crossref","first-page":"e5577","DOI":"10.1097\/MD.0000000000005577","volume":"95","author":"Y Li","year":"2016","unstructured":"Li Y, Lin J, Peng C (2016) Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: a case report and literature review. Medicine (Baltimore) 95:e5577","journal-title":"Medicine (Baltimore)"},{"key":"259_CR63","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1016\/j.atherosclerosis.2021.06.689","volume":"331","author":"M Abdelnabi","year":"2021","unstructured":"Abdelnabi M, Saleh Y, Badran H, Almaghraby A (2021) The efficacy and safety of rivaroxaban use in left atrial appendage thrombi. Atherosclerosis 331:e224","journal-title":"Atherosclerosis"},{"key":"259_CR64","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ahj.2016.05.007","volume":"178","author":"GY Lip","year":"2016","unstructured":"Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, van Eickels M, Cohen A (2016) Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J 178:126\u2013134","journal-title":"Am Heart J"},{"key":"259_CR65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5114\/aoms.2019.86616","volume":"16","author":"R Piotrowski","year":"2019","unstructured":"Piotrowski R, Zaborska B, Pilichowska-Paszkiet E, Sikora-Fr\u0105c M, Baran J, Ku\u0142akowski P (2019) RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study. Arch Med Sci AMS 16:289\u2013296","journal-title":"Arch Med Sci AMS"},{"key":"259_CR66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-9560-11-26","volume":"11","author":"T Kawakami","year":"2013","unstructured":"Kawakami T, Kobayakawa H, Ohno H, Tanaka N, Ishihara H (2013) Resolution of left atrial appendage thrombus with apixaban. Thromb J 11:26","journal-title":"Thromb J"},{"key":"259_CR67","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2169\/internalmedicine.8893-17","volume":"56","author":"T Okada","year":"2017","unstructured":"Okada T, Takaekou Y, Idei N, Ohashi N, Kaseda S (2017) Resolution of left atrial appendage thrombus with apixaban in a patient with heart failure. Intern Med 56:2891\u20132894","journal-title":"Intern Med"},{"key":"259_CR68","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","volume":"39","author":"MD Ezekowitz","year":"2018","unstructured":"Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt NS, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P (2018) Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 39:2959\u20132971","journal-title":"Eur Heart J"},{"key":"259_CR69","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1093\/eurheartj\/ehx390","volume":"38","author":"P Vranckx","year":"2017","unstructured":"Vranckx P, Windecker S, Welsh RC, Valgimigli M, Mehran R, Dangas G (2017) Thrombo-embolic prevention after transcatheter aortic valve implantation. Eur Heart J 38:3341\u20133350","journal-title":"Eur Heart J"},{"key":"259_CR70","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2017.02.051","volume":"69","author":"R Puri","year":"2017","unstructured":"Puri R, Auffret V, Rod\u00e9s-Cabau J (2017) Bioprosthetic valve thrombosis. J Am Coll Cardiol 69:2193\u20132211","journal-title":"J Am Coll Cardiol"},{"key":"259_CR71","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-0037-1607457","volume":"44","author":"S Sorrentino","year":"2018","unstructured":"Sorrentino S, Giustino G, Moalem K, Indolfi C, Mehran R, Dangas GD (2018) Antithrombotic treatment after transcatheter heart valves implant. Semin Thromb Hemost 44:38\u201345","journal-title":"Semin Thromb Hemost"},{"key":"259_CR72","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","volume":"68","author":"GD Dangas","year":"2016","unstructured":"Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R (2016) Prosthetic heart valve thrombosis. J Am Coll Cardiol 68:2670\u20132689","journal-title":"J Am Coll Cardiol"},{"key":"259_CR73","doi-asserted-by":"crossref","first-page":"e02","DOI":"10.15420\/icr.2019.24","volume":"15","author":"A Greco","year":"2020","unstructured":"Greco A, Capodanno D (2020) Anticoagulation after transcatheter aortic valve implantation: current status. Interv Cardiol (London, England) 15:e02\u2013e02","journal-title":"Interv Cardiol (London, England)"},{"key":"259_CR74","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","volume":"12","author":"D Jochheim","year":"2019","unstructured":"Jochheim D, Barbanti M, Capretti G, Stefanini GG, Hapfelmeier A, Zadrozny M, Baquet M, Fischer J, Theiss H, Todaro D, Chieffo A, Presbitero P, Colombo A, Massberg S, Tamburino C, Mehilli J (2019) Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv 12:1566\u20131576","journal-title":"JACC Cardiovasc Interv"},{"key":"259_CR75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","volume":"382","author":"GD Dangas","year":"2020","unstructured":"Dangas GD, Tijssen JGP, W\u00f6hrle J, S\u00f8ndergaard L, Gilard M, M\u00f6llmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimar\u00e3es AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Sch\u00e4fer U, Seeger J, Tch\u00e9tch\u00e9 D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S (2020) A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 382:120\u2013129","journal-title":"N Engl J Med"},{"key":"259_CR76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2018.03.008","volume":"200","author":"JP Collet","year":"2018","unstructured":"Collet JP, Berti S, Cequier A, Van Belle E, Lefevre T, Leprince P, Neumann FJ, Vicaut E, Montalescot G (2018) Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. Am Heart J 200:44\u201350","journal-title":"Am Heart J"},{"key":"259_CR77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2018.07.006","volume":"205","author":"NM Van Mieghem","year":"2018","unstructured":"Van Mieghem NM, Unverdorben M, Valgimigli M, Mehran R, Boersma E, Baber U, Hengstenberg C, Shi M, Chen C, Saito S, Veltkamp R, Vranckx P, Dangas GD (2018) Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial. Am Heart J 205:63\u201369","journal-title":"Am Heart J"},{"key":"259_CR78","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206\u20131214","journal-title":"N Engl J Med"},{"key":"259_CR79","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","volume":"16","author":"AR Dur\u00e3es","year":"2016","unstructured":"Dur\u00e3es AR, de Souza RP, de Almeida NB, Albuquerque FP, de Bulh\u00f5es FV, de Souza Fernandes AM, Aras R (2016) Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D 16:149\u2013154","journal-title":"Drugs R D"},{"key":"259_CR80","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2018.06.015","volume":"122","author":"AR Dur\u00e3es","year":"2018","unstructured":"Dur\u00e3es AR, Bitar YSL, Lima MLG, Santos CC, Schonhofen IS, Filho JAL, Roever L (2018) Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis. Am J Cardiol 122:1047\u20131050","journal-title":"Am J Cardiol"},{"key":"259_CR81","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimar\u00e3es","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros e Silva PG, Liporace IL, Sampaio RO, Tarasoutchi F, Hoffmann-Filho CR, de Lemos Soares Patriota R, Leiria TL, Lamprea D (2020) Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 383:2117\u20132126","journal-title":"N Engl J Med"},{"key":"259_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2021.01.127","author":"CY Shim","year":"2021","unstructured":"Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, Hong G-R, Lee CJ, Shin D-H, Ha J-W (2021) Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg. https:\/\/doi.org\/10.1016\/j.jtcvs.2021.01.127","journal-title":"J Thorac Cardiovasc Surg"},{"key":"259_CR83","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/jce.12214","volume":"24","author":"JM Jennings","year":"2013","unstructured":"Jennings JM, Robichaux R, McElderry HT, Plumb VJ, Gunter A, Doppalapudi H, Osorio J, Yamada T, Kay GN (2013) Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. J Cardiovasc Electrophysiol 24:1125\u20131129","journal-title":"J Cardiovasc Electrophysiol"},{"key":"259_CR84","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.amjcard.2012.12.046","volume":"111","author":"CP Rowley","year":"2013","unstructured":"Rowley CP, Bernard ML, Brabham WW, Netzler PC, Sidney DS, Cuoco F, Sturdivant JL, Leman RB, Wharton JM, Gold MR (2013) Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol 111:1165\u20131168","journal-title":"Am J Cardiol"},{"key":"259_CR85","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","volume":"36","author":"R Cappato","year":"2015","unstructured":"Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, H\u00fcgl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A (2015) Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 36:1805\u20131811","journal-title":"Eur Heart J"},{"key":"259_CR86","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","volume":"376","author":"H Calkins","year":"2017","unstructured":"Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M (2017) Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 376:1627\u20131636","journal-title":"N Engl J Med"},{"key":"259_CR87","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.amjcard.2019.10.033","volume":"125","author":"A Makani","year":"2020","unstructured":"Makani A, Saba S, Jain SK, Bhonsale A, Sharbaugh MS, Thoma F, Wang Y, Marroquin OC, Lee JS, Estes NAM, Mulukutla SR (2020) Safety and efficacy of direct oral anticoagulants versus warfarin in patients with chronic kidney disease and atrial fibrillation. Am J Cardiol 125:210\u2013214","journal-title":"Am J Cardiol"},{"key":"259_CR88","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40261-021-01016-7","volume":"41","author":"HY Chen","year":"2021","unstructured":"Chen HY, Ou SH, Huang CW, Lee PT, Chou KJ, Lin PC, Su YC (2021) Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis. Clin Drug Investig 41:341\u2013351","journal-title":"Clin Drug Investig"},{"key":"259_CR89","doi-asserted-by":"crossref","first-page":"4383269","DOI":"10.1155\/2019\/4383269","volume":"2019","author":"S Elhosseiny","year":"2019","unstructured":"Elhosseiny S, Al Moussawi H, Chalhoub JM, Lafferty J, Deeb L (2019) Direct oral anticoagulants in cirrhotic patients: current evidence and clinical observations. Can J Gastroenterol Hepatol 2019:4383269","journal-title":"Can J Gastroenterol Hepatol"},{"key":"259_CR90","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/1060028019841582","volume":"53","author":"TD Steuber","year":"2019","unstructured":"Steuber TD, Howard ML, Nisly SA (2019) Direct oral anticoagulants in chronic liver disease. Ann Pharmacother 53:1042\u20131049","journal-title":"Ann Pharmacother"},{"key":"259_CR91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fmed.2020.00107","volume":"7","author":"K Deng","year":"2020","unstructured":"Deng K, Cheng J, Rao S, Xu H, Li L, Gao Y (2020) Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. Front Med 7:107","journal-title":"Front Med"},{"key":"259_CR92","doi-asserted-by":"crossref","unstructured":"Rutherford O-CW, Jonasson C, Ghanima W, S\u00f6derdahl F and Halvorsen S. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. Heart 2022; 108: 345\u2013352.","DOI":"10.1136\/heartjnl-2020-318753"},{"key":"259_CR93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ana.26267","volume":"91","author":"AA Polymeris","year":"2022","unstructured":"Polymeris AA, Macha K, Paciaroni M, Wilson D, Koga M, Cappellari M, Schaedelin S, Zietz A, Peters N, Seiffge DJ (2022) Oral anticoagulants in the oldest old with recent stroke and atrial fibrillation. Ann Neurol 91:78\u201388","journal-title":"Ann Neurol"},{"key":"259_CR94","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2019.1.3","author":"M Abdelnabi","year":"2020","unstructured":"Abdelnabi M, Almaghraby A, Saleh Y (2020) Will direct oral anticoagulants have a chance in prosthetic valves? Eur Cardiol Rev. https:\/\/doi.org\/10.15420\/ecr.2019.1.3","journal-title":"Eur Cardiol Rev"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-022-00259-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-022-00259-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-022-00259-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:06:00Z","timestamp":1648512360000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-022-00259-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1186\/s43044-022-00259-9","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"All the authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}